Résumé
<p><b>OBJECTIVE</b>To investigate the value of technetium-99m methoxyisobutylisonitrile ((99)Tc(m)-MIBI) imaging in predicting the efficacy of neoadjuvant chemotherapy (NCT) and prognosis in patients with operable breast cancer.</p><p><b>METHODS</b>Sixty five patients with breast cancer underwent (99)Tc(m)-MIBI scintimammography before NCT, and static planar images were taken at 10 min and 180 min after scintimammography. The clearance rate was calculated in each patient, correlation between the clearance rate and efficacy of NCT, and the disease free survival rate were analyzed.</p><p><b>RESULTS</b>The mean clearance rate of 65 patients was (17.4 ± 6.8)%. The efficacy of NCT was 86.2% (CR 4 cases, PR 52 cases, SD 8 cases, and PD 1 case), and the mean clearance rate of patients with good response or poor response of chemotherapy were (15.5 ± 5.0)% and (29.2 ± 3.2)%, respectively. There was a significant difference between the two groups. The average disease free survival rate in the group with low clearance rate was (75.8%, P = 0.046), significantly higher than that in the group with high clearance rate (53.1%).</p><p><b>CONCLUSION</b>Scintimammography of (99)Tc(m)-MIBI may be used to evaluate the efficacy and prognosis of NCT for patients with operable breast cancer.</p>
Sujets)
Adulte , Sujet âgé , Femelle , Humains , Adulte d'âge moyen , Protocoles de polychimiothérapie antinéoplasique , Utilisations thérapeutiques , Tumeurs du sein , Imagerie diagnostique , Traitement médicamenteux , Carcinome canalaire du sein , Imagerie diagnostique , Traitement médicamenteux , Carcinome lobulaire , Imagerie diagnostique , Traitement médicamenteux , Traitement médicamenteux adjuvant , Cyclophosphamide , Utilisations thérapeutiques , Survie sans rechute , Épirubicine , Utilisations thérapeutiques , Étoposide , Utilisations thérapeutiques , Fluorouracil , Utilisations thérapeutiques , Études de suivi , Traitement néoadjuvant , Stadification tumorale , Valeur prédictive des tests , Scintigraphie , Radiopharmaceutiques , Induction de rémission , Taxoïdes , Utilisations thérapeutiques , Technétium (99mTc) sestamibiRésumé
<p><b>BACKGROUND</b>Keratinocyte serum-free medium (K-SFM) is a defined medium used to support the growth of primary keratinocytes and embryonic stem cell. The aim of this research was to optimize enrichment of breast cancer stem cells (CSCs) using K-SFM.</p><p><b>METHODS</b>A K-SFM was used to enrich CSCs from two breast cancer cell lines and a primary culture of breast cancer. RPMI-1640 supplemented with 10% fetal calf serum (FCS) was used as a control. CSCs were identified with flow cytometry using CD44(+)/CD24(-) as molecular markers. The expression of a variety of CSC markers (Oct-4, ABCG2, Nanog, N-cadherin, and E-cadherin) was analyzed with real-time PCR.</p><p><b>RESULTS</b>Much higher percentage of CSCs was achieved with K-SFM: 17.3% for MCF-7 cells, 17.4% for SKBR-3, and 20.0% for primary breast cancer culture. Less than 1% CSC was achieved using RPMI-1640 supplemented with 10% FCS. In comparison to the CSCs obtained with RPMI-1640, CSCs in the K-SFM expressed higher levels of Oct-4, ABCG2, Nanog and N-cadherin, and lower level of E-cadherin.</p><p><b>CONCLUSION</b>K-SFM is an optimal culture medium to maintain and to enrich breast CSCs.</p>